Literature DB >> 29871021

Emerging Technologies for the Diagnosis of Perihilar Cholangiocarcinoma.

Sumera Rizvi1, John Eaton1, Ju Dong Yang1, Vinay Chandrasekhara1, Gregory J Gores1.   

Abstract

The diagnosis of malignant biliary strictures remains problematic, especially in the perihilar region and in primary sclerosing cholangitis (PSC). Conventional cytology obtained during endoscopic retrograde cholangiography (ERC)-guided brushings of biliary strictures is suboptimal due to limited sensitivity, albeit it remains the gold standard with a high specificity. Emerging technologies are being developed and validated to address this pressing unmet patient need. Such technologies include enhanced visualization of the biliary tree by cholangioscopy, intraductal ultrasound, and confocal laser endomicroscopy. Conventional cytology can be aided by employing complementary and advanced cytologic techniques such as fluorescent in situ hybridization (FISH), and this technique should be widely adapted. Interrogation of bile and serum by examining extracellular vesicle number and cargo, and exploiting next-generation sequencing and proteomic technologies, is also being explored. Examination of circulating cell-free deoxyribonucleic acid (cfDNA) for differentially methylated regions is a promising test which is being rigorously validated. The special expertise required for these analyses has to date hampered their validation and adaptation. Herein, we will review these emerging technologies to inform the reader of the progress made and encourage further studies, as well as adaptation of validated approaches. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29871021      PMCID: PMC6463495          DOI: 10.1055/s-0038-1655775

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  77 in total

1.  Endoscopic ultrasound and fine-needle aspiration of unexplained bile duct strictures.

Authors:  Jeffrey H Lee; Ronald Salem; Harry Aslanian; Mary Chacho; Mark Topazian
Journal:  Am J Gastroenterol       Date:  2004-06       Impact factor: 10.864

2.  Biliary brush cytology and the detection of cholangiocarcinoma in primary sclerosing cholangitis: evaluation of specific cytomorphologic features and CA19-9 levels.

Authors:  Paul S Furmanczyk; Verena S Grieco; S Nicholas Agoff
Journal:  Am J Clin Pathol       Date:  2005-09       Impact factor: 2.493

3.  Positron emission tomography is not a reliable method for the early diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis.

Authors:  Johan Fevery; Otto Buchel; Frederik Nevens; Chris Verslype; Sigrid Stroobants; Werner Van Steenbergen
Journal:  J Hepatol       Date:  2005-08       Impact factor: 25.083

4.  Triple-tissue sampling at ERCP in malignant biliary obstruction.

Authors:  J Jailwala; E L Fogel; S Sherman; K Gottlieb; J Flueckiger; L G Bucksot; G A Lehman
Journal:  Gastrointest Endosc       Date:  2000-04       Impact factor: 9.427

5.  The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis.

Authors:  Cynthia Levy; James Lymp; Paul Angulo; Gregory J Gores; Nicholas Larusso; Keith D Lindor
Journal:  Dig Dis Sci       Date:  2005-09       Impact factor: 3.199

6.  Differentiation between benign and malignant hilar obstructions using laboratory and radiological investigations: a prospective study.

Authors:  Sundeep Singh Saluja; Raju Sharma; Sujoy Pal; Peush Sahni; Tushar Kanti Chattopadhyay
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

7.  Systemic spread is an early step in breast cancer.

Authors:  Yves Hüsemann; Jochen B Geigl; Falk Schubert; Piero Musiani; Manfred Meyer; Elke Burghart; Guido Forni; Roland Eils; Tanja Fehm; Gert Riethmüller; Christoph A Klein
Journal:  Cancer Cell       Date:  2008-01       Impact factor: 31.743

8.  Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution.

Authors:  Michelle L DeOliveira; Steven C Cunningham; John L Cameron; Farin Kamangar; Jordan M Winter; Keith D Lillemoe; Michael A Choti; Charles J Yeo; Richard D Schulick
Journal:  Ann Surg       Date:  2007-05       Impact factor: 12.969

9.  EUS-guided FNA of regional lymph nodes in patients with unresectable hilar cholangiocarcinoma.

Authors:  Ferga C Gleeson; Elizabeth Rajan; Michael J Levy; Jonathan E Clain; Mark D Topazian; Gavin C Harewood; Georgios I Papachristou; Naoki Takahashi; Charles B Rosen; Gregory J Gores
Journal:  Gastrointest Endosc       Date:  2007-12-03       Impact factor: 9.427

10.  Correlating routine cytology, quantitative nuclear morphometry by digital image analysis, and genetic alterations by fluorescence in situ hybridization to assess the sensitivity of cytology for detecting pancreatobiliary tract malignancy.

Authors:  Emily G Barr Fritcher; Benjamin R Kipp; Jeffrey M Slezak; Laura E Moreno-Luna; Gregory J Gores; Michael J Levy; Lewis R Roberts; Kevin C Halling; Thomas J Sebo
Journal:  Am J Clin Pathol       Date:  2007-08       Impact factor: 2.493

View more
  13 in total

Review 1.  Cholangiocarcinoma.

Authors:  Paul J Brindley; Melinda Bachini; Sumera I Ilyas; Shahid A Khan; Alex Loukas; Alphonse E Sirica; Bin Tean Teh; Sopit Wongkham; Gregory J Gores
Journal:  Nat Rev Dis Primers       Date:  2021-09-09       Impact factor: 65.038

2.  NTCP Change in Rats of Hilar Cholangiocarcinoma and Therapeutic Significance.

Authors:  Meng-Yu Zhang; Ming Luo; Kai He; Xian-Ming Xia; Jie-Ping Wang
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

Review 3.  Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic.

Authors:  Massimiliano Cadamuro; Alberto Lasagni; Angela Lamarca; Laura Fouassier; Maria Guido; Samantha Sarcognato; Enrico Gringeri; Umberto Cillo; Mario Strazzabosco; Jose Jg Marin; Jesus M Banales; Luca Fabris
Journal:  Expert Opin Investig Drugs       Date:  2021-02-23       Impact factor: 6.206

Review 4.  Diagnostic-therapeutic management of bile duct cancer.

Authors:  José María Huguet; Miriam Lobo; José Mir Labrador; Carlos Boix; Cecilia Albert; Luis Ferrer-Barceló; Ana B Durá; Patricia Suárez; Isabel Iranzo; Mireia Gil-Raga; Celia Baez de Burgos; Javier Sempere
Journal:  World J Clin Cases       Date:  2019-07-26       Impact factor: 1.337

5.  A novel prognostic nomogram for patients with surgically resected perihilar cholangiocarcinoma: a SEER-based study.

Authors:  Pengfei Li; Lujun Song
Journal:  Ann Transl Med       Date:  2021-01

6.  The impact of primary sclerosing cholangitis or inflammatory bowel disease on cholangiocarcinoma phenotype, therapy, and survival.

Authors:  Daljeet Chahal; Chris Shamatutu; Bill Salh; Janine Davies
Journal:  JGH Open       Date:  2020-08-11

Review 7.  Role of Endoscopy in Primary Sclerosing Cholangitis.

Authors:  Purnima Bhat; Lars Aabakken
Journal:  Clin Endosc       Date:  2020-05-08

8.  DNA Methylation Markers for Detection of Cholangiocarcinoma: Discovery, Validation, and Clinical Testing in Biliary Brushings and Plasma.

Authors:  Ju Dong Yang; Hassan Ghoz; Mohammed M Aboelsoud; William R Taylor; Tracy C Yab; Calise K Berger; Xiaoming Cao; Patrick H Foote; Nasra H Giama; Emily G Barr Fritcher; Douglas W Mahoney; Catherine D Moser; Thomas C Smyrk; Benjamin R Kipp; Gregory J Gores; Lewis R Roberts; John B Kisiel
Journal:  Hepatol Commun       Date:  2021-05-03

9.  Early Cholangiocarcinoma Detection With Magnetic Resonance Imaging Versus Ultrasound in Primary Sclerosing Cholangitis.

Authors:  John E Eaton; Christopher L Welle; Zeinab Bakhshi; Shannon P Sheedy; Ilkay S Idilman; Gregory J Gores; Charles B Rosen; Julie K Heimbach; Timucin Taner; Denise M Harnois; Keith D Lindor; Nicholas F LaRusso; Andrea A Gossard; Konstantinos N Lazaridis; Sudhakar K Venkatesh
Journal:  Hepatology       Date:  2021-04-19       Impact factor: 17.425

Review 10.  Practical review for diagnosis and clinical management of perihilar cholangiocarcinoma.

Authors:  Daniele Dondossola; Michele Ghidini; Francesco Grossi; Giorgio Rossi; Diego Foschi
Journal:  World J Gastroenterol       Date:  2020-07-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.